Contribution of individual adiponectin isoforms to lipolysis regulation remains unknown. We investigated the impact of full-length, trimeric and globular adiponectin isoforms on spontaneous lipolysis in subcutaneous abdominal (SCAAT) and visceral adipose tissues (VAT) of obese and non-obese subjects. Furthermore, we explored the role of AMPK (5'-AMP-activated protein kinase) in adiponectin-dependent lipolysis regulation and expression of adiponectin receptors type 1 and 2 (AdipoR1 and AdipoR2) in SCAAT and VAT. Primary adipocytes isolated from SCAAT and VAT of obese and non-obese women were incubated with 20 µg/ml of: A) full-length adiponectin (physiological mixture of all adiponectin isoforms), B) trimeric adiponectin isoform or C) globular adiponectin isoform. Glycerol released into media was used as a marker of lipolysis. While full-length adiponectin inhibited lipolysis by 22% in non-obese SCAAT, globular isoform inhibited lipolysis by 27% in obese SCAAT. No effect of either isoform was detected in non-obese VAT, however trimeric isoform inhibited lipolysis by 21% in obese VAT (all p<0.05). Trimeric isoform induced Thr172 p-AMPK in differentiated preadipocytes from a non-obese donor, while globular isoform induced Ser79 p-ACC by 32% (p<0.05) and Ser565 p-HSL by 52% (p = 0.08) in differentiated preadipocytes from an obese donor. AdipoR2 expression was 17% and 37% higher than AdipoR1 in SCAAT of obese and non-obese groups and by 23% higher in VAT of obese subjects (all p<0.05). In conclusion, the anti-lipolytic effect of adiponectin isoforms is modified with obesity: while full-length adiponectin exerts anti-lipolytic action in non-obese SCAAT, globular and trimeric isoforms show anti-lipolytic activity in obese SCAAT and VAT, respectively.

Department of Sport Medicine 3rd Faculty of Medicine Charles University Prague Czech Republic ; 2nd Internal Medicine Department University Hospital of Kralovske Vinohrady Prague Czech Republic

Zobrazit více v PubMed

Klein S, Burke LE, Bray GA, Blair S, Allison DB, et al. (2004) Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110: 2952–2967. PubMed

Zhang H, Cui J, Zhang C (2010) Emerging role of adipokines as mediators in atherosclerosis. World J Cardiol 2: 370–376. PubMed PMC

Arner P (2002) Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 18 Suppl 2S5–S9. PubMed

Kolditz CI, Langin D (2010) Adipose tissue lipolysis. Curr Opin Clin Nutr Metab Care 13: 377–381. PubMed

Opie LH, Walfish PG (1963) Plasma free fatty acid concentrations in obesity. N Engl J Med 268: 757–760. PubMed

Karpe F, Dickmann JR, Frayn KN (2011) Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 60: 2441–2449. PubMed PMC

Lafontan M, Langin D (2009) Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res 48: 275–297. PubMed

Arner P (2005) Human fat cell lipolysis: Biochemistry, regulation and clinical role. Best Practice & Research Clinical Endocrinology & Metabolism 19: 471–482. PubMed

Langin D, Arner P (2006) Importance of TNFalpha and neutral lipases in human adipose tissue lipolysis. Trends Endocrinol Metab 17: 314–320. PubMed

Laurencikiene J, van Harmelen, V, Arvidsson NE, Dicker A, Blomqvist L, et al. (2007) NF-kappaB is important for TNF-alpha-induced lipolysis in human adipocytes. Journal of Lipid Research 48: 1069–1077. PubMed

Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, et al. (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 89: 5577–5582. PubMed

van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, et al. (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005–3010. PubMed

Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731–737. PubMed

Wedellova Z, Dietrich J, Siklova-Vitkova M, Kolostova K, Kovacikova M, et al. (2011) Adiponectin inhibits spontaneous and catecholamine-induced lipolysis in human adipocytes of non-obese subjects through AMPK-dependent mechanisms. Physiol Res 60: 139–148. PubMed

Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, et al. (2003) Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278: 40352–40363. PubMed

Polak J, Kovacova Z, Jacek M, Klimcakova E, Kovacikova M, et al. (2007) An increase in plasma adiponectin multimeric complexes follows hypocaloric diet-induced weight loss in obese and overweight premenopausal women. Clin Sci (Lond) 112: 557–565. PubMed

Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98: 2005–2010. PubMed PMC

Tsao TS, Lodish HF, Fruebis J (2002) ACRP30, a new hormone controlling fat and glucose metabolism. European Journal of Pharmacology 440: 213–221. PubMed

Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, et al. (2007) Adiponectin stimulates AMP-Activated protein kinase in the hypothalamus and increases food intake. Cell Metabolism 6: 55–68. PubMed

Wu XD, Motoshima H, Mahadev K, Stalker TJ, Scalia R, et al. (2003) Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52: 1355–1363. PubMed

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288–1295. PubMed

Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152–12162. PubMed

Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, et al. (2003) Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 278: 50810–50817. PubMed

Hardie DG (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25: 1895–1908. PubMed PMC

Liu Q, Gauthier MS, Sun L, Ruderman N, Lodish H (2010) Activation of AMP-activated protein kinase signaling pathway by adiponectin and insulin in mouse adipocytes: requirement of acyl-CoA synthetases FATP1 and Acsl1 and association with an elevation in AMP/ATP ratio. FASEB J 24: 4229–4239. PubMed PMC

Dole VP (1956) A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J Clin Invest 35: 150–154. PubMed PMC

Kovacova Z, Tencerova M, Roussel B, Wedellova Z, Rossmeislova L, et al. (2011) The impact of obesity on secretion of adiponectin multimeric isoforms differs in visceral and subcutaneous adipose tissue. Int J Obes (Lond) 36: 1360–5. PubMed

Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 99: 16309–16313. PubMed PMC

Addabbo F, Nacci C, De BL, Leo V, Tarquinio M, et al. (2011) Globular adiponectin counteracts VCAM-1-mediated monocyte adhesion via AdipoR1/NF-kappaB/COX-2 signaling in human aortic endothelial cells. Am J Physiol Endocrinol Metab 301: E1143–E1154. PubMed PMC

Xiao X, Dong Y, Zhong J, Cao R, Zhao X, et al. (2011) Adiponectin protects endothelial cells from the damages induced by the intermittent high level of glucose. Endocrine 40: 386–393. PubMed

Chedid P, Hurtado-Nedelec M, Marion-Gaber B, Bournier O, Hayem G, et al. (2012) Adiponectin and its globular fragment differentially modulate the oxidative burst of primary human phagocytes. Am J Pathol 180: 682–692. PubMed

Ibrahim MM (2010) Subcutaneous and visceral adipose tissue: structural and functional differences. Obesity Reviews 11: 11–18. PubMed

Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, et al. (2006) Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome. Diabetologia 49: 2723–2728. PubMed

Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784–1792. PubMed PMC

Bluher M, Williams CJ, Kloting N, Hsi A, Ruschke K, et al. (2007) Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 30: 3110–3115. PubMed PMC

Nannipieri M, Bonotti A, Anselmino M, Cecchetti F, Madec S, et al. (2007) Pattern of expression of adiponectin receptors in human adipose tissue depots and its relation to the metabolic state. Int J Obes (Lond) 31: 1843–1848. PubMed

Qiao L, Kinney B, Schaack J, Shao J (2011) Adiponectin inhibits lipolysis in mouse adipocytes. Diabetes 60: 1519–1527. PubMed PMC

Garton AJ, Yeaman SJ (1990) Identification and role of the basal phosphorylation site on hormone-sensitive lipase. European Journal of Biochemistry 191: 245–250. PubMed

Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, et al. (2005) Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146: 790–796. PubMed

Kim JE, Song SE, Kim YW, Kim JY, Park SC, et al. (2010) Adiponectin inhibits palmitate-induced apoptosis through suppression of reactive oxygen species in endothelial cells: involvement of cAMP/protein kinase A and AMP-activated protein kinase. J Endocrinol 207: 35–44. PubMed

Wu X, Mahadev K, Fuchsel L, Ouedraogo R, Xu SQ, et al. (2007) Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signaling. Am J Physiol Endocrinol Metab 293: E1836–E1844. PubMed

Hurley RL, Barre LK, Wood SD, Anderson KA, Kemp BE, et al. (2006) Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem 281: 36662–36672. PubMed

Yin W, Mu J, Birnbaum MJ (2003) Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis In 3T3-L1 adipocytes. J Biol Chem 278: 43074–43080. PubMed

Dostalova I, Kavalkova P, Haluzikova D, Housova J, Matoulek M, et al. (2009) The use of microdialysis to characterize the endocrine production of human subcutaneous adipose tissue in vivo. Regul Pept 155: 156–162. PubMed

Kovacova Z, Vitkova M, Kovacikova M, Klimcakova E, Bajzova M, et al. (2009) Secretion of adiponectin multimeric complexes from adipose tissue explants is not modified by very low calorie diet. Eur J Endocrinol 160: 585–592. PubMed

Guilherme A, Virbasius JV, Puri V, Czech MP (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367–377. PubMed PMC